Aprea Therapeutics, Inc. (APRE) — SEC Filings
Aprea Therapeutics, Inc. (APRE) — 34 SEC filings. Latest: EFFECT (Apr 30, 2026). Includes 20 8-K, 6 10-Q, 2 DEF 14A.
View Aprea Therapeutics, Inc. on SEC EDGAR
Overview
Aprea Therapeutics, Inc. (APRE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 1, 2026: Aprea Therapeutics, Inc. filed an 8-K on April 1, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). The filing includes an interactive data document and exhibits, such as EX-99.1, and is related to their pharmaceutical preparations business
Sentiment Summary
Across 34 filings, the sentiment breakdown is: 2 bearish, 32 neutral. The dominant filing sentiment for Aprea Therapeutics, Inc. is neutral.
Filing Type Overview
Aprea Therapeutics, Inc. (APRE) has filed 1 EFFECT, 20 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 2 SC 13G, 1 SC 13G/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (34)
Risk Profile
Risk Assessment: Of APRE's 24 recent filings, 2 were flagged as high-risk, 11 as medium-risk, and 11 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1,848 |
| Net Income | ($2,972,410) |
| EPS | ($0.47) |
| Debt-to-Equity | N/A |
| Cash Position | $13,718,052 |
| Operating Margin | N/A |
| Total Assets | $14,321,316 |
| Total Debt | $0 |
Key Executives
- Oren Gilad, Ph.D.
Industry Context
Aprea Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel cancer therapies. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success often depends on securing substantial funding for clinical trials and navigating complex patent landscapes.
Top Tags
8-K (7) · financials (5) · regulatory-filing (4) · 10-Q (4) · disclosure (3) · material-agreement (3) · 8-k (3) · sec-filing (3) · Aprea Therapeutics (3) · equity-sale (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC Accession Number | 0001104659-26-038258 | Unique identifier for this filing |
| Cash and cash equivalents | $13.7M | As of September 30, 2025, down from $22.8M at Dec 31, 2024, insufficient for 12 months of operations. |
| Net loss for Q3 2025 | $2,972,410 | Improved from $3,783,769 in Q3 2024. |
| Net loss for nine months ended Sep 30, 2025 | $10,143,939 | Slightly increased from $10,063,912 in the same period of 2024. |
| Grant revenue for Q3 2025 | $1,848 | Significant decrease from $354,621 in Q3 2024. |
| Grant revenue for nine months ended Sep 30, 2025 | $282,422 | Significant decrease from $1,296,764 in the same period of 2024. |
| Research and development expenses for Q3 2025 | $1,638,917 | Decreased from $2,846,399 in Q3 2024. |
| General and administrative expenses for Q3 2025 | $1,480,319 | Decreased from $1,605,238 in Q3 2024. |
| Common shares outstanding | 6,310,673 | As of November 11, 2025. |
| Commission File Number | 001-39069 | Identifies the company's SEC filing history. |
| IRS Employer Identification No. | 84-2246769 | Company's tax identification number. |
| Net loss | $7.17M | For the six months ended June 30, 2025, increased from $6.28M in 2024 |
| Grant revenue | $280.5K | For the six months ended June 30, 2025, a significant decrease from $942.1K in 2024 |
| Research and development expenses | $4.39M | For the six months ended June 30, 2025, an increase from $4.15M in 2024 |
| Net cash used in operating activities | $6.76M | For the six months ended June 30, 2025 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Aprea Therapeutics, Inc. (APRE)?
Aprea Therapeutics, Inc. has 34 recent SEC filings from Jan 2024 to Apr 2026, including 20 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of APRE filings?
Across 34 filings, the sentiment breakdown is: 2 bearish, 32 neutral. The dominant sentiment is neutral.
Where can I find Aprea Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Aprea Therapeutics, Inc. (APRE) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Aprea Therapeutics, Inc.?
Key financial highlights from Aprea Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for APRE?
The investment thesis for APRE includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Aprea Therapeutics, Inc.?
Key executives identified across Aprea Therapeutics, Inc.'s filings include Oren Gilad, Ph.D..
What are the main risk factors for Aprea Therapeutics, Inc. stock?
Of APRE's 24 assessed filings, 2 were flagged high-risk, 11 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Aprea Therapeutics, Inc.?
Forward guidance and predictions for Aprea Therapeutics, Inc. are extracted from SEC filings as they are enriched.